TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03592472: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Sponsor: Xynomic Pharmaceuticals, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 413 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT03592472 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03592472 Rescue Dossier →